kabutan

Chordia Therapeutics Inc.(190A) Summary

190A
TSE Growth
Chordia Therapeutics Inc.
129
JPY
+5
(+4.03%)
Mar 13, 3:30 pm JST
0.80
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
128
Mar 13, 11:47 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.12
Yield
ー%
Margin Trading Ratio
531.43
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
123 JPY 0.77 USD
Previous Close Mar 12
124 JPY 0.78 USD
High Mar 13, 1:54 pm
131 JPY 0.82 USD
Low Mar 13, 9:00 am
123 JPY 0.77 USD
Volume
688,300
Trading Value
0.09B JPY 0.55M USD
VWAP
127.69 JPY 0.8 USD
Minimum Trading Value
12,900 JPY 80 USD
Market Cap
9.41B JPY 0.06B USD
Number of Trades
203
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
507
1-Year High Feb 27, 2026
11,759
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 5,318,700
Feb 27, 2026 172,100 5,123,900 29.77
Feb 20, 2026 0 4,364,300
Feb 13, 2026 0 4,329,500
Feb 6, 2026 0 4,310,300
Company Profile
Chordia Therapeutics Inc. engages in the development of cancer therapeutics targeting RNA regulation stress.
Sector
Pharmaceuticals
Chordia Therapeutics Inc. is a drug discovery venture company specializing in the research and development of novel anti-cancer drugs targeting RNA regulation stress. The company has multiple pipelines including CLK inhibitors, MALT1 inhibitors, and CDK12 inhibitors, aiming to create groundbreaking first-in-class pharmaceuticals. Clinical trials are currently underway for acute myeloid leukemia, ovarian cancer, and other indications. Chordia Therapeutics actively promotes collaborative research and licensing partnerships with universities, public institutions, and pharmaceutical companies to achieve efficient drug discovery operations. The company is also expanding its partnering strategy, as exemplified by the licensing agreement for MALT1 inhibitors with Ono Pharmaceutical Co., Ltd.